Key facts
- It has raised $1.8M; the latest was Later Stage VC ($110K) in Dec 2025.
- Notable investors include Berkeley SkyDeck, Berkeley SkyDeck Fund, Capital BioVentures, Cibersons, District 3 Innovation Center — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Cura Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Cura Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cura Therapeutics
Developer of a next-generation drug discovery platform designed to reprogram the immune system to fight complex diseases, including metastatic cancer, age-related conditions, and pathogen infections. The company offers an AI-driven protein modeling and pathway analysis approach, combining functional assays to engineer immune fusion proteins, enabling targeted treatment of tumors and reducing the risk of systemic toxicity, ultimately improving therapeutic outcomes for patients with cancer and age-related diseases.
- Sector
- Healthcare
- HQ
- Ottawa, Canada
- Founded
- 2017
- Employees
- 5
- Website
- curatherapeutics.com/
- Ownership
- Privately Held (backing)
Cura Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cura Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cura Therapeutics in its N-PORT filings yet. We sweep new filings monthly.